Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02292082 · ClinicalTrials.gov registry record · Phase 4

The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

A Phase 4 study of Osteoarthritis, sponsored by Hospital for Special Surgery, New York.

Completed
Registry status
Phase 4
Development phase
111
Enrollment target
1
Study location

NCT02292082 is a Phase 4 study of Osteoarthritis that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 111 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02292082, a Phase 4 study of Osteoarthritis, has completed, sponsored by Hospital for Special Surgery, New York.

COMPLETED
Registry status
Phase 4
Development phase
111 participants
Enrollment target
1
Study location

Study Summary

Total knee replacement is associated with severe post-operative pain. The purpose of this study is to compare two methods of treatment for pain control following Total Knee Replacement with an accelerated physical therapy protocol to aid the achievement of rehab milestones.

Conditions Studied

Interventions

  • DRUG Bupivacaine
  • DRUG Normal saline
  • DRUG Methylprednisolone
  • DRUG Cefazolin
  • DRUG Morphine

Study Locations (1)

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2014-11
Est. Completion 2016-08
Phase Phase 4

What the Registry Record Tells You About NCT02292082

The ClinicalTrials.gov registry entry for NCT02292082 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (86% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 5 interventions - of which Bupivacaine is the first listed.

NCT02292082 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02292082 about?

NCT02292082 is a clinical study titled "The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)". Total knee replacement is associated with severe post-operative pain. The purpose of this study is to compare two methods of treatment for pain control following Total Knee Replacement with an accelerated physical therapy protocol to aid the achievement of rehab milestones.

What is the current status of trial NCT02292082?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2014-11. Estimated completion is 2016-08.

What conditions does trial NCT02292082 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT02292082?

The interventions under investigation include: Bupivacaine (DRUG), Normal saline (DRUG), Methylprednisolone (DRUG), Cefazolin (DRUG), Morphine (DRUG).

Who is sponsoring clinical trial NCT02292082?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02292082 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.